Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications [PDF]
Molecules, 2021 Aldose reductase (AR, ALR2), the first enzyme of the polyol pathway, is implicated in the pathophysiology of diabetic complications. Aldose reductase inhibitors (ARIs) thus present a promising therapeutic approach to treat a wide array of diabetic ...
Lucia Kovacikova +5 more
doaj +2 more sources
Aldose Reductase Inhibitors [PDF]
Journal of Enzyme Inhibition, 2001 Aldose reductase ([EC1.1.1.21]: AR) acts on the first step of the polyol metabolic pathway to catalyze the reduction of glucose to sorbitol with NADPH as a coenzyme. Hyperactivity of the pathway in individuals with high blood glucose level is closely related to the onset or progression of diabetic complications.
M, Oka, N, Kato
openaire +2 more sources
WJ-39, an Aldose Reductase Inhibitor, Ameliorates Renal Lesions in Diabetic Nephropathy by Activating Nrf2 Signaling. [PDF]
Oxid Med Cell Longev, 2020 Zhou X +9 more
europepmc +3 more sources
Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan. [PDF]
J Diabetes Investig, 2019 Sekiguchi K +9 more
europepmc +3 more sources
BMC Chemistry, 2021 In diabetes, increased accumulation of sorbitol has been associated with diabetic complications through polyol pathway. Aldose reductase (AR) is one of the key factors involved in reduction of glucose to sorbitol, thereby its inhibition is important for ...
Mohsinul Mulk Bacha +8 more
doaj +1 more source
Sugar Alcohols Have a Key Role in Pathogenesis of Chronic Liver Disease and Hepatocellular Carcinoma in Whole Blood and Liver Tissues. [PDF]
, 2020 The major risk factors for hepatocellular carcinoma (HCC) are hepatitis C and B viral infections that proceed to Chronic Liver Disease (CLD). Yet, the early diagnosis and treatment of HCC are challenging because the pathogenesis of HCC is not fully ...
El-Said, Hala +5 more
core +2 more sources
Cardiovascular Diabetology, 2023 Background Cardiovascular diseases, including diabetic cardiomyopathy, are major causes of death in people with type 2 diabetes. Aldose reductase activity is enhanced in hyperglycemic conditions, leading to altered cardiac energy metabolism and ...
Keshav Gopal +11 more
doaj +1 more source
Aldose reductase inhibitors inhibit the oxidative stress response of human bronchial epithelial cell line BEAS-2 induced by house dust mite [PDF]
Jichu yixue yu linchuang, 2022 Objective To investigate the inhibition of house dust mite induced oxidative stress with human bronchial epithelial cell line BEAS-2B by aldose reductase inhibitor (ARIs). Methods BEAS-2B was divided into control group, model group, NF-κB inhibitor group
BAO Min, LIN Mei, ZHEN Hai-ning, HE Fang, DING Min, YUAN Zhu-qing, CHEN Ya-jun, XUE Xin-xin
doaj +1 more source
Aldose reductase inhibitors: 2013-present [PDF]
Expert Opinion on Therapeutic Patents, 2019 Aldose reductase (ALR2) is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status.
Quattrini L., La Motta C.
openaire +3 more sources
Frontiers in Endocrinology, 2021 Diabetes is a leading cause of cardiovascular morbidity and mortality. Despite numerous treatments for cardiovascular disease (CVD), for patients with diabetes, these therapies provide less benefit for protection from CVD.
Sravya Jannapureddy +4 more
doaj +1 more source